SCHEMBL15515566

SCHEMBL15515566

O=C(O)c1cc2ccc(Cl)c(Cl)c2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.56
HSD17B10 Q99714 3/20 0.56
ALDH1A1 P00352 3/20 0.56
MEN1 O00255 1/20 0.56
USP2 O75604 1/20 0.56
KMT2A Q03164 1/20 0.56
EIF4A3 P38919 2/20 0.49
F7 P08709 1/20 0.49
F3 P13726 1/20 0.49
DAO P14920 3/20 0.47
APEX1 P27695 2/20 0.46
KDM4E B2RXH2 3/20 0.44
MAPT P10636 1/20 0.44
SRD5A2 P31213 1/20 0.44
RHEB Q15382 1/20 0.44
SMAD3 P84022 1/20 0.42
CSNK2A2 P19784 1/20 0.41
CSNK2B P67870 1/20 0.41
CSNK2A1 P68400 1/20 0.41
LMNA P02545 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26912440 0.84 CCNC (0.40) HPGDHSD17B10ALDH1A1MEN1USP2
SCHEMBL23346530 0.84 HPGD (0.54) HPGDHSD17B10ALDH1A1MEN1USP2
SCHEMBL27530562 0.83 HPGD (0.53) HPGDHSD17B10ALDH1A1MEN1USP2
SCHEMBL3605104 0.83 HPGD (0.53) HPGDHSD17B10ALDH1A1MEN1USP2
SCHEMBL8959651 0.83 EIF4A3 (0.54) HPGDHSD17B10ALDH1A1MEN1USP2
SCHEMBL7677228 0.83 EIF4A3 (0.61) HPGDHSD17B10ALDH1A1MEN1USP2
SCHEMBL30310477 0.83 EIF4A3 (0.61) HPGDHSD17B10ALDH1A1MEN1USP2
SCHEMBL24740292 0.80 ALOX15 (0.57) KMT2ALMNA
SCHEMBL1144741 0.79 HPGD (0.60) HPGDHSD17B10ALDH1A1MEN1USP2
SCHEMBL24019762 0.77 ALOX15 (0.60) ALDH1A1EIF4A3KDM4EMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116857-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS PARDES BIOSCIENCES INC (US) 2026-04-30 US disclosed
EP-4660193-A1 INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2025-12-10 EP disclosed
US-12145911-B2 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2024-11-19 US disclosed
US-20240270693-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2024-08-15 US disclosed
WO-2024162746-A1 INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF 한국화학연구원 2024-08-08 WO disclosed
US-11858945-B2 Alkyne-containing antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2024-01-02 US disclosed
US-20230391786-A1 cGAS INHIBITORS ELI LILLY AND COMPANY 2023-12-07 US disclosed
WO-2023235809-A1 CGAS INHIBITORS ELI LILLY AND COMPANY (US) 2023-12-07 WO disclosed
CN-116685576-A Cysteine protease inhibitors and methods of use thereof 美商帕迪斯生物科学公司 2023-09-01 CN disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20200354379-A1 NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AICURIS GMBH & CO. KG (DE) 2020-11-12 US disclosed
EP-3704127-A1 NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AiCuris GmbH & Co. KG (DE) 2020-09-09 EP disclosed
CN-111448199-A Novel highly active amino-thiazole-substituted indole-2-carboxamides having activity against Hepatitis B Virus (HBV) 艾库里斯有限及两合公司 2020-07-24 CN disclosed
EP-2892880-B1 INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2017-11-22 EP disclosed
US-20160355477-A1 INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2016-12-08 US disclosed
US-9447039-B2 Indole carboxamide derivatives and uses thereof NOVARTIS AG (CH) 2016-09-20 US disclosed
EP-2892880-A1 INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF Novartis AG (CH) 2015-07-15 EP disclosed
US-20150175539-A1 INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2015-06-25 US disclosed
WO-2014037900-A1 INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2014-03-13 WO disclosed
CN-1265591-A Coumpound ZENECA LTD (GB) 2000-09-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116857-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS CTRC, CTRL, CTSL HPGD 3164/4885HSD17B10 856/4885ALDH1A1 3293/4885
US-20150175539-A1 INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF TPH1, TPH2, IARS2 HPGD 883/4885HSD17B10 876/4885ALDH1A1 613/4885
US-20240270693-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSV, CTSL HPGD 1608/4885HSD17B10 1711/4885ALDH1A1 2252/4885
US-20160355477-A1 INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF TPH1, TPH2, IARS2 HPGD 883/4885HSD17B10 876/4885ALDH1A1 613/4885
US-20230391786-A1 cGAS INHIBITORS CGAS, STING1, TBK1 HPGD 1300/4885HSD17B10 2509/4885ALDH1A1 4135/4885
US-11858945-B2 Alkyne-containing antiviral agents ACE, SARS1, ACE2 HPGD 3962/4885HSD17B10 700/4885ALDH1A1 876/4885
US-12145911-B2 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL HPGD 1608/4885HSD17B10 1711/4885ALDH1A1 2252/4885
US-20200354379-A1 NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) HCCS, CDK2, BRD4 HPGD 2387/4885HSD17B10 1978/4885ALDH1A1 3863/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV HPGD 1219/4885HSD17B10 1162/4885ALDH1A1 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.